Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Treg-depleted donor lymphocyte infusion
- Development stage
- Phase 2
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Treg-depleted donor lymphocyte infusion (DLI) is an adoptive cellular immunotherapy developed by Assistance Publique - Hôpitaux de Paris for the treatment of relapsed hematological malignancies following allogeneic hematopoietic stem cell transplantation (HSCT). The therapy involves the infusion of donor lymphocytes from which regulatory T cells (Tregs) have been selectively removed. Tregs are known to suppress anti-tumor immune responses; by depleting them, the graft-versus-leukemia (GVL) effect of the donor T cells is enhanced. While earlier strategies targeted CD25 for depletion, this specific approach utilizes CD127 (interleukin-7 receptor alpha) positive selection to more effectively isolate and remove the Treg population, thereby amplifying the allogeneic immune response against malignant cells.
- Other names
- Regulatory T cell-depleted donor lymphocyte infusionCD127-selected Treg-depleted DLICD-127-selected Treg-depleted DLICD 127-selected Treg-depleted DLI
Beyond the preview
Go deeper on Treg-depleted donor lymphocyte infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Treg-depleted donor lymphocyte infusion.